Related Experiment Videos
Clinical evaluation of peptichemio
Cancer Treatment Reports
|March 1, 1979
Summary
Peptichemio, a peptide complex of m-L-phenylalanine mustard, showed a 7% partial remission rate in solid tumors. Key side effects included myelotoxicity and phlebitis, with an optimal dose of 45 mg/m2/day for 3 days.
Area of Science:
- Oncology
- Pharmacology
Background:
- Peptichemio is a peptide complex derived from m-L-phenylalanine mustard.
- Clinical efficacy and toxicity of novel chemotherapeutic agents are crucial in cancer treatment.
Purpose of the Study:
- To evaluate the clinical efficacy and toxicity of Peptichemio in patients with solid tumors.
- To determine the optimal dose schedule and identify potential toxicities associated with Peptichemio administration.
Main Methods:
- A clinical trial involving 116 patients with solid tumors.
- Peptichemio administered intravenously (iv) at doses ranging from 20-75 mg/m2/day for 3 days, with courses repeated every 3-4 weeks.
Main Results:
- 104 patients were evaluable for toxicity and response.
- The optimal dose schedule identified was 45 mg/m2/day for 3 days.
- A 7% partial remission rate was observed across various solid tumors, including melanoma, lymphoma, and carcinomas of the gastrointestinal, genitourinary, breast, and head and neck.
- Major side effects included cumulative myelotoxicity, phlebitis, and mild nausea/vomiting, with no other major organ toxicity noted.
- Responses lasted between 4-36 weeks.
Conclusions:
- Peptichemio demonstrates modest efficacy in solid tumors, with a 7% partial remission rate.
- The recommended optimal dose is 45 mg/m2/day for 3 days.
- Cumulative myelotoxicity and phlebitis are the primary dose-limiting toxicities, necessitating careful patient monitoring.